PRELIMINARY NOTE The unaudited condensed Consolidated Financial Statements for the three-month period ended March 31, 2023, included herein, have been prepared in. | May 4, 2023
Lyon, France – 12 April 2023 – 6pm CEST – Theranexus, a biopharmaceutical company innovating in the treatment of rare neurological diseases and pioneer in the development of drug. | April 12, 2023
Lyon, France - 12 April 2023 - 6pm CEST - Theranexus, a biopharmaceutical company innovating in the treatment of rare neurological diseases and pioneer in the development of drug candidates modulating
Conference call to discuss financial and operational results scheduled for Thursday, March 16, at 8:30 a.m. U.S. Eastern Time Executed global licensing and.
Theranexus, Inria, Claude Bernard University Lyon 1 and Hospices Civils de Lyon today announced the launch of the new public-private project team "AlstroSight". The project team aims to develop innovative digital methods to identify new drug candidates designed to treat brain diseases, in particular certain rare neurological disorders.